AUROPHARMA vs BIOFILCHEM: Stock Comparison
Aurobindo Pharma Limited vs Biofil Chemicals & Pharmaceuticals Limited
Live data: 22 July 2026, 1:33 PM IST • Source: NSE and company filings
Aurobindo Pharma Limited is the larger company by market capitalisation. Aurobindo Pharma Limited shows a higher dividend yield, faster revenue growth and a higher net margin, while Biofil Chemicals & Pharmaceuticals Limited shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Side-by-side comparison of Aurobindo Pharma Limited and Biofil Chemicals & Pharmaceuticals Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AUROPHARMA | BIOFILCHEM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AUROPHARMA | BIOFILCHEM |
|---|---|---|
| Live Price | ₹1,534.1 | ₹33.15 |
| Day Change | -2.89% | -1.57% |
| Volume | 15.38 L | 971 |
| 52-Week High | ₹1,636.8 | ₹46.34 |
| 52-Week Low | ₹1,016.1 | ₹25.6 |
| Distance from 52W High | -6.27% | -28.46% |
Valuation
| Metric | AUROPHARMA | BIOFILCHEM |
|---|---|---|
| Market Cap | ₹88,263 Cr | ₹55 Cr |
| P/E Ratio | 26.03x | — |
| P/B Ratio | 2.41x | — |
| EPS | ₹60.36 | ₹1.71 |
| Book Value | ₹652.31 | ₹13.21 |
| Dividend Yield | 0.26% | 0% |
Growth
| Metric | AUROPHARMA | BIOFILCHEM |
|---|---|---|
| Revenue Growth (TTM YoY) | 5.6% | -9.3% |
| EPS Growth (TTM YoY) | 1.9% | 10.8% |
| Qtr Sales Growth | 5.62% | -9.34% |
| Qtr Profit Growth | 1.97% | 5% |
Profitability & Leverage
| Metric | AUROPHARMA | BIOFILCHEM |
|---|---|---|
| ROE | 10.1% | 13.8% |
| ROCE | 12.8% | 15.8% |
| Net Margin | 10.62% | 9.81% |
| Operating Margin | 20.3% | 2.29% |
| Debt to Equity | 0.21x | 0.14x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AUROPHARMA | BIOFILCHEM |
|---|---|---|
| Promoter Holding | 48.81%▲ 0.06 pp | 46.79% |
| FII Holding | 16.38%▲ 1.14 pp | 0% |
| DII Holding | 25.1%▼ 0.77 pp | 0.08% |
| Public Holding | 6.64%▼ 0.44 pp | 53.13% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Aurobindo Pharma Limited and Biofil Chemicals & Pharmaceuticals Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.